MRV Research

A Preclinical Tale for Melanoma: The Aspirin and the Antibody

MRV Research, Of Interest

A preclinical study using mouse and human melanoma cell lines published in a September, 2015, issue of Cell, outlines mechanisms by which melanoma can evade the immune system. They found that cyclooxygenase (COX)-driven prostaglandin E2 enables malignant growth of melanoma through evasion of immune mechanisms, and suggest that COX inhibitors could be useful adjuvants for immune-based therapies.1

Read More
MRV News
Melanoma News
Archive
Menu